Celldex (CLDX) Therapeutics announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells via stem cell factor starvation.
Education
About Us
Working with TipRanks
Follow Us
1